Northwestern Mutual Wealth Management Co. Purchases 56,582 Shares of Hims & Hers Health, Inc. $HIMS

Key Points

• Northwestern Mutual Wealth Management massively increased its Hims & Hers position in the fourth quarter, adding 56,582 shares and lifting its stake to 57,114 shares valued at about $1.85 million.
• Insider trading was mixed: CFO Oluyemi Okupe sold 36,922 shares under a pre-arranged trading plan, while Director David B. Wells bought 48,400 shares for about $1.17 million, a move investors may view as bullish.
• Analyst sentiment remains cautious overall despite some price target increases; the stock has a consensus Hold rating with an average target of $28.70, and the company recently missed earnings estimates even though revenue rose year over year.

Northwestern Mutual Wealth Management Co. increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 10,635.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 57,114 shares of the company's stock after acquiring an additional 56,582 shares during the period. Northwestern Mutual Wealth Management Co.'s holdings in Hims & Hers Health were worth $1,854,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HIMS. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter worth $28,000. Binnacle Investments Inc bought a new stake in Hims & Hers Health during the 3rd quarter worth $28,000. Bogart Wealth LLC lifted its holdings in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company's stock worth $29,000 after buying an additional 632 shares during the period. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter worth about $30,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock worth $47,000 after buying an additional 687 shares during the period. Institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 36,922 shares of the business's stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $25.90, for a total value of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares of the company's stock, valued at $7,300,355.30. The trade was a 11.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells bought 48,400 shares of the firm's stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the transaction, the director directly owned 224,417 shares in the company, valued at $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 212,807 shares of company stock worth $5,473,644 over the last three months. Insiders own 11.76% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on HIMS. Needham & Company LLC lifted their target price on Hims & Hers Health from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. cut their target price on Hims & Hers Health from $35.00 to $33.00 and set an "overweight" rating on the stock in a report on Tuesday, May 12th. Truist Financial lifted their target price on Hims & Hers Health from $18.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, May 22nd. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a report on Tuesday, May 12th. Finally, Canaccord Genuity Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.70.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Director David B. Wells bought 48,400 shares for about $1.17 million at $24.23 per share, increasing his stake by 27.5%. Investors often view insider buying as a bullish signal that management believes the stock is undervalued. Hims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million Buy
• Positive Sentiment: Another report highlighted the same insider purchase and noted Hims & Hers gained about 5% intraday on the news, reinforcing that the stock’s move is being driven by bullish insider sentiment. Hims & Hers Gains 5% on Insider Buying
• Neutral Sentiment: Analyst commentary comparing Hims & Hers with Tempus AI may keep attention on HIMS as an AI-healthcare growth story, but it does not appear to be a direct catalyst for the stock move today. HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
• Negative Sentiment: Bank of America lowered its price target on HIMS to $25 from $28 and warned that the company may need a significant ramp in GLP-1 subscriber growth to meet 2026 guidance, which adds a cautionary note for investors. Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA

Hims & Hers Health Stock Up 5.8%

Shares of NYSE:HIMS opened at $25.24 on Thursday. The company has a market capitalization of $5.84 billion, a price-to-earnings ratio of -280.41, a P/E/G ratio of 46.28 and a beta of 2.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The business's 50-day moving average is $24.02 and its 200-day moving average is $27.59. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.20 earnings per share. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.